Abstract
Purpose
Mediastinal small cell carcinoma (MSCC) is a rare tumor with limited published literature. In view of diagnostic confusion pertaining to this tumor, we investigated its origin, clinical features, management and survival.
Methods
Clinical data of MSCC patients were retrospectively reviewed. Eligible patients showed pathologically proven small cell carcinoma (SCC) with the primary lesions confined to the mediastinum. Survival information was collected through follow-up studies.
Results
Among 25 MSCC patients identified, 22 were classified to have limited disease (LD), while 3 were with extensive disease (ED). The 5 patients (20 %) underwent surgery and 20 patients (80 %) underwent non-surgical treatment. The 4 patients with LD MSCC received chemotherapy alone, while 13 of them received chemoradiotherapy. Overall median survival time (MST) of all patients was 22 months, and the 1-, 3- and 5-year overall survival rates were 67.4, 16.8, and 8.4 %, respectively. The MST of LD and ED patients separately was 23 and 8 months, respectively, with significant difference (P = 0.005). But, the MST of patients who received surgical and non-surgical treatment was 25 and 21 months, respectively, with no significant difference (P = 0.757). The MST of LD patients receiving chemotherapy and chemoradiotherapy was 12 and 29 months, respectively, but somehow did not show significant difference (P = 0.482).
Conclusions
Our data suggested that MSCC may be a separate clinical entity like extrapulmonary small cell carcinomas (EPSCCs). Despite, multimodal treatment is currently the main treatment option, but for patients with LD MSCC, chemoradiotherapy is recommended to be preferred treatment modality.
Similar content being viewed by others
References
Stamatis G. Neuroendocrine tumors of the lung: the role of surgery in small cell lung cancer. Thorac Surg Clin. 2014;24:313–26.
Carter BW, Glisson BS, Truong MT, Erasmus JJ. Small cell lung carcinoma: staging, imaging, and treatment considerations. Radiographics. 2014;34:1707–21.
Remick SC, Ruckdeschel JC. Extrapulmonary and pulmonary small-cell carcinoma: tumor biology, therapy, and outcome. Med Pediatr Oncol. 1992;20:89–99.
Frazier SR, Kaplan PA, Loy TS. The pathology of extrapulmonary small cell carcinoma. Semin Oncol. 2007;34:30–8.
Duguid J, Kennedy A. Oat cell tumors of mediastinal glands. J Pathol Bacteriol. 1930;33:93–9.
Dakhil CS, Wick JA, Kumar AK, Satyan MT, Neupane P. Extrapulmonary small cell carcinoma: the University of Kansas experience and review of literature. Med Oncol. 2014;31:187.
Walenkamp AM, Sonke GS, Sleijfer DT. Clinical and therapeutic aspects of extrapulmonary small cell carcinoma. Cancer Treat Rev. 2009;35:228–36.
Lobins R, Floyd J. Small cell carcinoma of unknown primary. Semin Oncol. 2007;34:39–42.
Howard S, O’Regan K, Jagannathan J, Krajewski K, Giardino A, Ramaiya N. Extrapulmonary small cell carcinoma: a pictorial review. AJR Am J Roentgenol. 2011;197:W392–8.
Terada T. Primary small cell carcinoma of the mediastinum: a case report with immunohistochemical and molecular genetic analyses of KIT and PDGFRA genes. Med Oncol. 2009;26:247–50.
Takanami I, Imamura T, Yamamoto Y, Yamamoto T, Kodaira S. Long survival in small-cell (neuroendocrine) carcinoma of the mediastinum. Scand J Thorac Cardiovasc Surg. 1996;30:179–80.
Yang CC, Lee HS, Chen CC, Cheng CJ, Lin SH. Syndrome of inappropriate antidiuretic hormone secretion in a patient with cryptococcal meningoencephalitis: a hidden mediastinal small cell carcinoma. Am J Med Sci. 2006;331:288–91.
Oyaizu T, Okada Y, Sagawa M, Yamakawa K, Kuroda H, Fujihara K, et al. Lambert-Eaton myasthenic syndrome associated with an anterior mediastinal small cell carcinoma. J Thorac Cardiovasc Surg. 2001;121:1005–6.
Igawa S, Murakami H, Yamamoto N. Thymic small cell carcinoma shows marked response to amrubicin. J Thorac Oncol. 2009;4:778.
Iwata T, Inoue K, Mizuguchi S, Morita R, Tsukioka T, Suehiro S. Thymic small cell carcinoma associated with pulmonary squamous cell carcinoma. Ann Thorac Surg. 2006;82:2266–8.
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.
Tscheikuna J, Suttinont P. Is cytology necessary in diagnosis of mediastinal mass? J Med Assoc Thai. 2009;92(Suppl 2):S24–9.
Brennan SM, Gregory DL, Stillie A, Herschtal A, Mac Manus M, Ball DL. Should extrapulmonary small cell cancer be managed like small cell lung cancer? Cancer. 2010;116:888–95.
Stinchcombe TE, Gore EM. Limited-stage small cell lung cancer: current chemoradiotherapy treatment paradigms. Oncologist. 2010;15:187–95.
Wong YN, Jack RH, Mak V, Henrik M, Davies EA. The epidemiology and survival of extrapulmonary small cell carcinoma in South East England, 1970–2004. BMC Cancer. 2009;9:209.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflict of interest.
Ethical approval
The study was approved by the Ethics Committees of all hospitals.
Informed consent
Informed consent has been obtained from the patients.
Funding
No funding received for this study.
Rights and permissions
About this article
Cite this article
Dai, W., Liu, M., Zhuang, X. et al. Mediastinal small cell carcinoma: a unique clinical entity?. Clin Transl Oncol 18, 515–520 (2016). https://doi.org/10.1007/s12094-015-1398-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12094-015-1398-4